Cullinan Oncology
CGEM
66 hedge funds and large institutions have $762M invested in Cullinan Oncology in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 12 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 11
3.67% more ownership
Funds ownership: 74.11% → 77.77% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less capital invested
Capital invested by funds: $795M → $762M (-$32.7M)
7% less funds holding
Funds holding: 71 → 66 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.1M |
| 2 |
BlackRock
New York
|
+$18.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$14M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.04M |
| 5 |
Goldman Sachs
New York
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$7.61M |
| 2 |
VA
VR Adviser
New York
|
-$7.22M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$7.1M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$4.26M |
| 5 |
EP
Eversept Partners
New York
|
-$4.22M |
CGEM Hedge Fund Activity: Q3 2021 in Review
66 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q3 2021, worth a combined $762M — down 4.1% from $795M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CGEM and 7 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 33 added.
The largest buyer was Vanguard Group, adding an estimated $30.1M. The largest seller was Ikarian Capital, exiting entirely with an estimated $7.61M sold.
- 66 institutional investors held Cullinan Oncology (CGEM) as of Q3 2021, down from 71 in Q2 2021.
- Funds reported $762M of Cullinan Oncology stock for Q3 2021, down 4.1% quarter-over-quarter.
- 7 funds opened new Cullinan Oncology positions in Q3 2021 and 12 closed out, a net change of -5 holders.
- The largest Cullinan Oncology buyer in Q3 2021 was Vanguard Group, an estimated $30.1M added.
- The largest Cullinan Oncology seller in Q3 2021 was Ikarian Capital, an estimated $7.61M sold.
Based on aggregated 13F filings for Q3 2021.